CLDX Share Price

Open 2.54 Change Price %
High 2.57 1 Day 0.00 0.00
Low 2.51 1 Week -0.10 -3.80
Close 2.53 1 Month 0.20 8.58
Volume 1026412 1 Year -1.16 -31.44
52 Week High 5.02
52 Week Low 2.20
CLDX Important Levels
Resistance 2 2.59
Resistance 1 2.56
Pivot 2.54
Support 1 2.50
Support 2 2.47
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
HMNY 5.70 63.79%
LOCM 0.09 50.00%
VALV 0.03 50.00%
SCHS 0.04 33.33%
GCFB 0.50 31.58%
OPNT 35.70 29.54%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
ZOOM 0.00 -100.00%
TXCC 0.01 -95.00%
AMCF 0.01 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
BDMS 4.10 -45.33%
More..

Celldex Therapeutics, Inc. (NASDAQ: CLDX)

CLDX Technical Analysis 2
As on 19th Sep 2017 CLDX Share Price closed @ 2.53 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.16 & Buy for SHORT-TERM with Stoploss of 2.47 we also expect STOCK to react on Following IMPORTANT LEVELS.
CLDX Target for September
1st Target up-side 2.72
2nd Target up-side 2.9
3rd Target up-side 3.09
1st Target down-side 2.2
2nd Target down-side 2.02
3rd Target down-side 1.83
CLDX Other Details
Segment EQ
Market Capital 363793952.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celldextherapeutics.com
CLDX Address
CLDX
Perryville III Building
53 Frontage Road
Hampton, NJ 08827
United States
Phone: 908-200-7500
Fax: 908-454-1911
CLDX Latest News
Interactive Technical Analysis Chart Celldex Therapeutics, Inc. ( CLDX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Celldex Therapeutics, Inc.
CLDX Business Profile
Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.